Online Supplements to

TFEB activation protects against cardiac proteotoxicity via increasing autophagic flux

Bo Pan¹, Hanming Zhang¹, Taixing Cui², Xuejun Wang¹*

¹Division of Basic Biomedical sciences, University of South Dakota Sanford School of Medicine, Vermillion, SD 57069, USA

²Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, SC 29209, USA

Running title: TFEB protects against cardiac proteotoxicity

*Correspondence: Dr. Xuejun Wang, Division of Basic Biomedical Sciences, Sanford School of Medicine of the University of South Dakota, Vermillion, SD 57069, USA. Telephone: 605 658-6345, Fax: 605 677-6381. E-mail: <u>xuejun.wang@usd.edu</u>.

- I. Supplementary Tables 1 ~ 3.
- II. Supplementary Figures 1 ~ 8.

I. Supplementary Tables 1 ~ 3.

Gene Name	Sequence (5'–3')	
CtsB	TGGGTTCAGCGAGGACAT	
	ATGGTGTAGGGTAAGCAGCC	
CtsD	GCGTCTTGCTGCTCATTCT	
	AACTCTGACACTGGCTCCTT	
Lamp1	GTGGGACTTGCGGTGCC	
	GACATTGAGGGCGAGCG	
M6PR	GGATAAGGAGTCAAAGAATG	
	TGATTCTCCCAACCACCGT	
MCOLN1	CGCCGCCGCCTCAAGT	
	GCTGCTCCCGTGTGTAGGC	
UVRAG	CTTCTGGATACCTACTTCAC	
	GACTTTCCACTCTATCAACAGC	
VPS18	GCTCCGCATTGACTTGGG	
	GCCTTCTGTCCATTGCGGT	
RAB7A	CAGTCTCTTGGTGTGGC	
	CGAAGTAAGGAATGTTG	
P62	GCCACCTCTCTGATAGC	
	AGGTTTGCTGACTTCCG	
BECN1	TTACTTACCACAGCCCAGG	
	TGCTCCAACATCTCCAAAC	
TFEB	GGTGTTGAAGGTGCAGTCC	
	GGGTAGCGTGTTGGGCATCTG	
E-CryAB	GGTGTTGAAGGTGCAGTCC	
	GGGTAGCGTGTTGGGCATCTG	
T-CryAB	TTCTTCGGAGAGCACCTGTT	
	TCTGGGACGTCGTATGGGTA	
GAPDH	ATGACATCAAGAAGGTGGTG	
	CATACCAGGAAATGAGCTTG	

Supplementary Table1. Primers used for RT-PCR

		B 120C
	NTG	CryAB ^{R120G} TG
	(n=8)	(n=8)
Heart rate (bpm)	473±25	336±26**
LV end-diastolic posterior wall thickness (mm)	0.76 ± 0.08	1.33±0.09**
LV end-diastolic volume (mm ³)	77.69±5.59	64.82±7.15**
LV Ejection Fraction (EF, %)	57.47±4.61	54.27±10.53
LV Fractional Shortening (FS, %)	29.98±3.07	28.00±6.71
Stroke Volume (SV, µl)	44.6±+3.7	34.8±6.2**
Cardiac Output (CO, ml/min)	21.2±2.2	12.0±2.2**
Estimated LV Mass (mg)	99.2±16.4	192.3±20.3**

Supplementary Table 2. Echocardiographic parameters of FVB/N mice at ~6 months of Age


LV, left ventricle; TG, transgenic; NTG, non-TG; **p<0.01 vs. NTG; Student's t-tests. Mean ± STD


	NTG (n=6)	CryAB ^{R120G} TG (n=6)
Heart Weight (mg)	122.2±15.8	212.2±14.0**
Tibial Length (mm)	18.6±0.9	18.7±0.6
Heart weight/Tibial length (mg/mm)	6.57±0.73	11.36±0.61**

Supplementary Table 3. Gravimetric analysis of FVB/N mice at ~6 months of Age


**p < 0.01 vs. NTG; Student's *t*-tests. Mean \pm STD

II. Supplementary Figures 1 ~ 8






kinase, and Gel C was for phospo-mTOR and phospo-p70 S6 kinase.



TFEB proteins in cultured cardiomyocytes. A and **B**, Western blot analyses for the indicated proteins in the total cell lysates from cultured NRVMs at 24 h after Ad-β-gal or Ad-HA-CryAB^{R120G} (R120G) infection. Overexpression of HA-CryAB^{R120G} was confirmed by the immnoblot for HA-tagged protein (middle image in A). Representative images (A) and pooled densitometry data of two major TFEB bands (B) are shown. N=4 biological repeats/treatment. **C** ~ **F**, Western blot analyses for the indicated proteins in the soluble (C, E) and insoluble (D, F) fraction of cultured NRVMs at 48 h after Ad-β-gal or Ad-HA-CryAB^{R120G} infection. Note that CryAB^{R120G} overexpression displayed no discernible effect on the expression of TFEB proteins in cultured cardiomyocytes. Mean+SEM, N=3 biological repeats/treatment. *p*>0.05 for all comparisons between the β-gal and the R120G groups at both 24 h and 48 h time points.



confocal microscopy were all performed as described for main text Figure 5.

